期刊文献+

丙种球蛋白无反应性川崎病的治疗研究 被引量:6

Treatment of Kawasaki disease patients with non-responsiveness to high-dose gamma-globulin therapy
下载PDF
导出
摘要 目的探讨对大剂量静脉注射丙种球蛋白(IVIG)无反应性川崎病(KD)的临床特点,以及再治疗方案的选择。方法收集2007年1月至2009年12月入院的140例IVIG无反应性的KD患儿,将患儿随机分为4组对照组(单用阿司匹林),IVIG追加治疗组(阿司匹林基础上加2 g.kg-1.d-1IVIG),泼尼松组(阿司匹林基础上加甲泼尼龙20~30 mg.kg-1.d-1)及乌司他丁治疗组(阿司匹林基础上加乌司他丁5 000 U.kg-1),比较各组的临床特点及治疗效果。结果单用阿司匹林治疗的对照组患儿,心脏冠状动脉病变(CAD)并发率明显高于IVIG追加治疗组、泼尼松组及乌司他丁组。且恢复时间较长。IVIG追加治疗组、泼尼松组及乌司他丁组治疗有效率明显高于对照组,但3组之间无统计学差异,且3组患儿CAD并发率相似。结论 IVIG无反应性川崎病较IVIG敏感性川崎病更易发生CAD和严重并发症;对IVIG无反应性川崎病可以用IVIG追加治疗、糖皮质激素或合用乌司他丁,都可以取得较好的疗效。 Objective To investigate the clinical characteristics and treatment plan of high-dose intravenous immunoglobulin(IVIG)non-responsive Kawasaki disease(KD).Methods A total of 140 KD patients with non-responsiveness to high-dose gamma-globulin therapy hospitalized from January 2007 to December 2009 were included in the study.All the KD patients were divided into 4 groups.The control group took aspirin orally only.The IVIG group were given intravenous immunoglobulin at 2 g·kg-1·d-1.The prednisone group were given intravenous meprednisone at 20-30 mg·kg-1·d-1.The ulinastatin group were given intravenous ulinastatin 5 000 U·kg-1.The clinical characteristics and therapeutic effect were analysed.Results The therapeutic effect rate in the control group was lower than that of the other groups.The incidence rate of coronary artery lesion was higher in the control group than the other groups.But there was no difference between the 3 groups in the effective rate and the incidence rate.Conclusion KD patients with IVIG non-responsiveness are vulnerable to coronary artery lesion and severe complications.Additional IVIG,steroid therapy and ulinastatin therapy may be used for IVIG non-responsive KD patients.
机构地区 湖南省儿童医院
出处 《中南药学》 CAS 2011年第4期307-309,共3页 Central South Pharmacy
关键词 丙种球蛋白 川崎病 乌司他丁 泼尼松 IVIG; Kawasaki disease; ulinastatin; prednisone
  • 相关文献

参考文献14

  • 1王慕逖.儿科学[M].北京:人民卫生出版社,2001:123.
  • 2Newburger JW,Takahashi M,Gerber MA,et al.Diagnosis,treatment,and long-term management of Kawasaki disease:a statement for health professionals from the Committee on Rheumatic Fever,Endocarditis,and Kawasaki Disease,Council on Cardiovascular Disease in the Young[J].American Heart Association Peadiatfies,2004,114(6):1708-1733.
  • 3Wallace CA,French JW,Kahn SJ,et al.Initial intravenous gamma-globulin treatment failure in Kawasaki disease[J].Pediatrics,2000,105(6):E78.
  • 4薛辛东.儿科学[M].北京:人民卫生出版社.2008:107.
  • 5胡亚美 江载芳.实用儿科学[M].北京:人民卫生出版社,2005.1249.
  • 6Wallace CA,French JW,Kahn SJ,et al.Initial intravenouse gammagloubin in treatment failure in Kawasaki disease[J].Pediatfies,2000,105(6):E78.
  • 7Fukunishi M,Kikkawa M,Hamana K.et al.Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset[J].J Pediatr,2000,137(2):172-176.
  • 8藤山纯一,堀野智史,齑藤徹,等.川崎病にけぉる免疫ク口フリン大量静注療法不(悶)例の臨床的検封[J].小儿科临床,2006,59(3):444-448.
  • 9陈嫕,王荣发,刘芳.对大剂量静脉丙种球蛋白初治无效的川崎病的处治及相关因素探讨[J].中国当代儿科杂志,2004,6(1):59-61. 被引量:9
  • 10杜忠东,张永兰,赵地,杜军保,鲁珊,衣京梅,侯安存,周忠蜀,丁国芳,林瑶,刘冲,北京小儿川崎病流行病学调查协作组.静脉丙种球蛋白无反应性川崎病的治疗及危险因素分析[J].中国实用儿科杂志,2006,21(10):738-741. 被引量:88

二级参考文献19

  • 1野中善男.かソフロブミソ不仄例[J].小儿科,2000,41(5):547-553.
  • 2胡亚美,江载芳,诸福棠.实用儿科学[M].7版.北京:人民卫生出版社,2002:1204-1205.
  • 3Du ZD,Zhang TH,Li T,et al.Epidemiologic pictures of Kawasaki disease in Beijing from 1995 through 1999[J].Pediat Infect Dis J,2002,21 (2):103-107.
  • 4Newburger JW,Takahashi M,Gerber MA,et al.Diagnosis,treatment,and long-term management of Kawasaki disease:a statement for health professionals from the Committee on Rheumatic Fever,Endocarditis and Kawasaki Disease,Council on Cardiovascular Disease in the Young,American Heart Association[J].Pediatrics,2004,114 ;1708-1733.[2]Newburger JW,Takahashi M,Gerber MA,et al.Diagnosis,treatment,and long-term management of Kawasaki disease:a statement for health professionals from the Committee on Rheumatic Fever,Endocarditis and Kawasaki Disease,Council on Cardiovascular Disease in the Young,American Heart Association[J].Pediatrics,2004,114 ;1708-1733.
  • 5Freeman AF,Shulman ST.Refractory Kawasaki disease[J].Pediatr Infect Dis J,2004,23(5):463-464.
  • 6Yanagawa H,Sonobe T.Changes in the diagnostic guidelines for Kawasaki disease.In:Yanagawa H,Nakamuru Y,Yashiro M,Kawasaki T,editors.Epidemiology of Kawasaki disease:a 30-year achievement[M].Tokyo:Shindan-To-Chiryosha,2004:24 -32.
  • 7Han RK,Silverman ED,Newman A,et al.Management and outcome of recurrent fever after intial intrarenous gammaglobulin therapy in acute Kawasaki disease[J].Arch Pediatr Adolesc Med,2000,154 (7):694-699.
  • 8Wright DA,Newburger JW,Baker A,et al.Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids[J].J Pediatr,1996,128:146-149.
  • 9Burns JC,Capparelli EV,Brown JA,et al.Intravenous gammaglobulin treatment and retreatment in Kawasakidisease.US/Canadian Kawasaki Syndrome Study Group[J].Pediatr Infect Dis J,1998,17:1144-1148.
  • 10Wallace CA,French JW,Kahn SJ,et al.Initial intravenous gammaglobulin treatment failure in Kawasaki disease[J].Pediatrics,2000,105(6):78-81.

共引文献235

同被引文献56

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部